Number, incidence (per 100 person-years) and hazard ratios for Infections reported as adverse events during follow-up among the 17 802 trial participants
| Intention-to-treat analysis | Analysis censored at cardiovascular or venous thrombosis event | |||||
|---|---|---|---|---|---|---|
| Infection | Rosuvastatin, no. (rate) | Placebo, no. (rate) | HR (95%CI) | Rosuvastatin, no. (rate) | Placebo, no. (rate) | HR (95%CI) |
| Pneumonia | 214 (1.12) | 257 (1.35) | 0.83 (0.69–1.00) | 203 (1.06) | 251 (1.31) | 0.81 (0.67–0.97) |
| Any respiratory infection | 2644 (17.36) | 2688 (17.77) | 0.98 (0.93–1.03) | 2627 (17.26) | 2659 (17.61) | 0.98 (0.93–1.04) |
| Soft-tissue infection | 417 (2.23) | 480 (2.58) | 0.87 (0.76–0.99) | 412 (2.20) | 471 (2.53) | 0.87 (0.76–0.99) |
| Gastrointestinal infection | 334 (1.77) | 342 (1.81) | 0.98 (0.84–1.14) | 328 (1.74) | 339 (1.80) | 0.97 (0.83–1.13) |
| Urinary tract infection | 798 (4.39) | 787(4.33) | 1.01 (0.92–1.12) | 788 (4.33) | 767 (4.22) | 1.03 (0.93–1.14) |
| Gynecologic infection | 200 (1.04) | 252 (1.32) | 0.79 (0.66–0.95) | 199 (1.04) | 245 (1.29) | 0.81 (0.67–0.98) |
| Viral infection | 740 (4.04) | 723 (3.94) | 1.02 (0.92–1.14) | 731 (3.99) | 708 (3.86) | 1.03 (0.93–1.15) |
| Fungal infection | 130 (0.68) | 164 (0.86) | 0.79 (0.63–1.00) | 125 (0.65) | 162 (0.85) | 0.77 (0.61–0.97) |
| Systemic sepsis | 59 (0.31) | 56 (0.29) | 1.05 (0.73–1.52) | 57 (0.30) | 47 (0.24) | 1.21 (0.82–1.78) |
Note: CI = confidence interval, HR = hazard ratio.